Stay informed with the latest litigation news. Explore now

IP Verse

Modernatx competitive analysis

Latest publications and patents of Modernatx New

Explore the latest publications and patents granted to Modernatx, showcasing their recent innovations and technological advancements.

Last updated on: Sep 7, 2025

Publication Number	Publication Date	Title	Legal Status
Get instant update for new patents of Modernatx
EP4594334	Aug 6, 2025	Purification Of Nucleotides By Means Of A Mixed-Mode Purification System	Pending
EP4577519	Jul 2, 2025	Methods For Purification Of Ionizable Lipids	Pending
EP4565694	Jun 11, 2025	Extraction-Less Reverse Phase (Rp) Chromatography For Mrna Purity Assessment	Pending
EP4565692	Jun 11, 2025	Internal Ribosome Entry Sites For Improved Polynucleotide Translation	Pending
EP4562163	Jun 4, 2025	Engineered Polynucleotides For Temporal Control Of Expression	Pending
EP4562141	Jun 4, 2025	Methods Of Rna Purification	Pending
EP4561638	Jun 4, 2025	Engineered Polynucleotides For Cell Selective Expression	Pending
EP4561547	Jun 4, 2025	Lipid Nanoparticle Compositions Comprising Phospholipid Derivatives And Related Uses	Pending
EP4561546	Jun 4, 2025	Lipid Nanoparticle Compositions Comprising Surface Lipid Derivatives And Related Uses	Pending
EP4554617	May 21, 2025	Norovirus Mrna Vaccines	Pending

Latest oppositions filed by Modernatx

Explore patent oppositions filed by Modernatx against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 11, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP4226941	Pegylated Liposomes For Delivery Of Immunogen-Encoding Rna	GLAXOSMITHKLINE	Jul 15, 2025
EP4241767	Novel Lipids And Compositions For The Delivery Of Therapeutics	ARBUTUS BIOPHARMA	Apr 29, 2025
EP2958588	Combination Of Vaccination And Inhibition Of The Pd-1 Pathway	CUREVAC	May 22, 2018
EP2279254	Novel Lipid Formulations For Nucleic Acid Delivery	ARBUTUS BIOPHARMA	Apr 5, 2018

Latest patents of Modernatx opposed by its competitors

Explore Modernatx's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 11, 2025

Patent Number	Grant Date	Title	Total Oppositions
EP3394030	Feb 12, 2025	Compounds And Compositions For Intracellular Delivery Of Agents	1
EP3981437	Oct 9, 2024	Nucleic Acid Vaccines	4
EP4023249	Oct 9, 2024	Nucleic Acid Vaccines	3
EP3853305	Oct 2, 2024	High-Purity Peg Lipids And Uses Thereof	6
EP3431485	Sep 4, 2024	Engineered Nucleic Acids And Methods Of Use Thereof	2
EP3917503	May 8, 2024	Methods Of Preparing Lipid Nanoparticles	1
EP3359670	Feb 14, 2024	Methods For Therapeutic Administration Of Messenger Ribonucleic Acid Drugs	1
EP3578652	Jul 12, 2023	Ribonucleic Acid Purification	1
EP3625345	May 24, 2023	Modified Messenger Rna Comprising Functional Rna Elements	2
EP3458083	Nov 2, 2022	Polynucleotides Encoding Interleukin-12 (Il12) And Uses Thereof	2

Latest PTAB cases involving Modernatx New

Discover the latest PTAB cases involving Modernatx, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 13, 2025

Proceeding Number	Filing Date	Petitioner	Respondent	Status
Get alerts for PTAB Cases involving Modernatx
IPR2023-01359	Aug 28, 2023	BIONTECH	MODERNATX	Final Written Decision - Appealed
IPR2023-01358	Aug 28, 2023	PFIZER	MODERNATX	Final Written Decision - Appealed
IPR2017-02194	Sep 29, 2017	MODERNATX	CUREVAC	Final Written Decision

Top competitors of Modernatx

Top competitors of Modernatx based on patent oppositions.

BIONTECH

SANOFI

PFIZER